<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00791817</url>
  </required_header>
  <id_info>
    <org_study_id>2005046B</org_study_id>
    <nct_id>NCT00791817</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Potential Food Effects</brief_title>
  <official_title>An Open-label, Single Dose, Randomized, Crossover Study to Evaluate Potential Food Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Procter and Gamble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Half the group will be given a high fat diet and the other half will fast. They will then be
      crossed over.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A food-effect study which will be conducted at any time during the MRD study period on one
      single cohort of subjects using 200 mg oral dose of PG 760564. Half the group will be given a
      high fat diet and the other half will fast. They will ten be crossed over.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>over 12 hours</time_frame>
    <description>Maximum plasma concentration after a single dose</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>200 mg PG 760564, Subjects Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg PG 760564, Subjects Fasted, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg PG 760564, Subjects Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg PG 760564, Subjects Fed high fat meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PG-760564</intervention_name>
    <description>200 mg capsule, single dose,fasted when dosed, duration is 4 days</description>
    <arm_group_label>200 mg PG 760564, Subjects Fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PG-760564</intervention_name>
    <description>200 mg capsule, single dose,high fat diet when dosed, duration is 4 days</description>
    <arm_group_label>200 mg PG 760564, Subjects Fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and surgically sterile or post-menopausal (last menstrual period &gt; 1
             year at the time of enrollment) healthy females, 18-45 years of age, inclusive, at
             screening;

          -  Who have not used tobacco or nicotine-containing products within the past 3 months;

          -  Willing to abstain from caffeine or xanthine-containing beverages, including coffee
             and tea, chocolate, alcohol, grapefruit juice, and Seville oranges, from 24 hours
             before admission and for the duration of the study;

          -  Who have a body mass index (BMI) between 18 and 32 kg/m2, inclusive.

        Exclusion Criteria:

          -  History of diabetes, cardiovascular, hepatic, renal, or malabsorptive disease;

          -  History of diabetes, cardiovascular, hepatic, renal, or malabsorptive disease;

          -  History of peptic ulcer disease, hemorrhoids, GI surgery (appendectomy and
             cholecystectomy are allowed), or GI bleeding;

          -  History of autoimmune disease;

          -  History of immunodeficiency or of unusual susceptibility to infectious diseases;

          -  History of tuberculosis, acquired immunodeficiency syndrome (AIDS), or infection with
             human immunodeficiency virus (HIV);

          -  Any history of hypersensitivity or clinically significant allergy to any drug;

          -  Personal or family history of prolonged QT syndrome or any cardiac conduction
             abnormality;

          -  Family history of sudden death;

          -  History of uveitis or inflammatory ocular disease;

          -  History of peptic ulcer disease, hemorrhoids, GI surgery (appendectomy and
             cholecystectomy are allowed), or GI bleeding;

          -  History of autoimmune disease;

          -  History of immunodeficiency or of unusual susceptibility to infectious diseases;

          -  History of tuberculosis, acquired immunodeficiency syndrome (AIDS), or infection with
             human immunodeficiency virus (HIV);

          -  Any history of hypersensitivity or clinically significant allergy to any drug;

          -  Personal or family history of prolonged QT syndrome or any cardiac conduction
             abnormality;

          -  Family history of sudden death;

          -  History of uveitis or inflammatory ocular disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William S Aronstein, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Procter and Gamble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stuart I Harris, MD, PhD</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2008</study_first_submitted>
  <study_first_submitted_qc>November 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2008</study_first_posted>
  <results_first_submitted>August 4, 2011</results_first_submitted>
  <results_first_submitted_qc>August 4, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 7, 2011</results_first_posted>
  <last_update_submitted>August 4, 2011</last_update_submitted>
  <last_update_submitted_qc>August 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>William S Aronstein, PhD, MD</name_title>
    <organization>Procter and Gamble Pharmaceuticals</organization>
  </responsible_party>
  <keyword>pharmacokinetics study</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>200 mg PG 760564. Fed Then Fasted</title>
          <description>200 mg PG 760564. subjects dosed in a Fed State, followed by a washout period, followed by 200 mg PG 760564 in a fasted state</description>
        </group>
        <group group_id="P2">
          <title>200 mg PG 760564. Fasted</title>
          <description>200 mg PG 760564. subjects dosed in a Fasted , followed by a washout period, followed by 200 mg PG 760564 in a Fed state</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>1: Single Dose Followed by Week Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>2: Single Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>200 mg PG 760564. Fed Then Fasted</title>
          <description>200 mg PG 760564. subjects dosed in a Fed State, followed by a washout period, followed by 200 mg PG 760564 in a fasted state</description>
        </group>
        <group group_id="B2">
          <title>200 mg PG 760564. Fasted</title>
          <description>200 mg PG 760564. subjects dosed in a Fasted , followed by a washout period, followed by 200 mg PG 760564 in a Fed state</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Study is a crossover study. All subjects received Investigational Product in BOTH the Fed and Fasted state</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.8" spread="10.0"/>
                    <measurement group_id="B2" value="31.8" spread="10.0"/>
                    <measurement group_id="B3" value="31.8" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>Maximum plasma concentration after a single dose</description>
        <time_frame>over 12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>200 mg PG 760564. Fed Then Fasted</title>
            <description>200 mg PG 760564. subjects dosed in a Fed State, followed by a washout period, followed by 200 mg PG 760564 in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>200 mg PG 760564. Fasted</title>
            <description>200 mg PG 760564. subjects dosed in a Fasted , followed by a washout period, followed by 200 mg PG 760564 in a Fed state</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum plasma concentration after a single dose</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2567.9" spread="652.6" lower_limit="1.20" upper_limit="1.61"/>
                    <measurement group_id="O2" value="3568.9" spread="633.2" lower_limit="1.20" upper_limit="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>values are Geometric Means and Confidence Intervals are on the Ratio of Fed to Fasted</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.3897</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1998</ci_lower_limit>
            <ci_upper_limit>1.6097</ci_upper_limit>
            <estimate_desc>Confidence Interval is on the Ratio of Fed to Fasted</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>200 mg PG 760564. Fed Then Fasted</title>
          <description>200 mg PG 760564. subjects dosed in a Fed State, followed by a washout period, followed by 200 mg PG 760564 in a fasted state</description>
        </group>
        <group group_id="E2">
          <title>200 mg PG 760564. Fasted</title>
          <description>200 mg PG 760564. subjects dosed in a Fasted , followed by a washout period, followed by 200 mg PG 760564 in a Fed state</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MeDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>heme-positive stool</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Data, calculations, interpretations, opinions, and recommendations are the property of P&amp;GP. In the event study results are published in the scientific literature by P&amp;GP, acknowledgment will be made to the Investigator(s) in the accepted style, as appropriate.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Thomas</name_or_title>
      <organization>Procter &amp; Gamble</organization>
      <phone>513.622.4838</phone>
      <email>thomas.pr@pg.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

